Final Prospectus Filed for Resale of 18.7M Shares by Lenders at $1.30 Exercise Price
CGC sits 42% above its 52-week low of $0.77 on light trading volume (0.3× avg).
Summary
Canopy Growth filed the final prospectus for the resale of 18.7 million common shares by lenders, tied to warrants with an exercise price of $1.30, potentially providing $24.3 million to the company upon exercise.
Key Events · Financing and Capital Events · CGC
-
Finalizes Resale Prospectus
This 424B3 serves as the final prospectus for the resale of 18.7 million common shares by selling securityholders, following the S-3 registration filed on February 6, 2026.
-
Warrants from Loan Agreement
The shares are issuable upon the exercise of warrants issued to lenders as part of a $150 million senior secured loan agreement completed on January 8, 2026.
-
Exercise Price Set
The warrants have an exercise price of US$1.30 per share, which is currently above the company's stock price of $1.09.
-
Potential Cash Infusion
If all warrants are exercised for cash, Canopy Growth could receive approximately $24.3 million, intended for investments, acquisitions, and general corporate purposes.
Analysis · CGC · Life Sciences
This 424B3 filing serves as the final prospectus for the resale of 18.7 million common shares by selling securityholders, which are issuable upon the exercise of warrants. These warrants were issued to lenders as part of a $150 million senior secured loan agreement on January 8, 2026. The exercise price of $1.30 per share is currently above the company's stock price of $1.09, meaning the warrants are out-of-the-money, which reduces immediate selling pressure. However, the registration creates an overhang, and if exercised, could provide Canopy Growth with approximately $24.3 million in proceeds, which would be used for investments, acquisitions, and general corporate purposes. This filing finalizes the terms of the offering initiated with the S-3 registration on February 6, 2026, and is part of the company's ongoing recapitalization efforts.
At the time of this filing, CGC was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.8M. The 52-week trading range was $0.77 to $2.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.